The founding scientific team, pioneers in the field of neuroimmunology, has over the last 30 years made major discoveries in the role of an inflammatory protein in brain functioning.  In the clinical setting, they have observed that blocking this protein has profound effects on many pathologies, demonstrating a primary mechanism that can be targeted for treatment of pathologies including:

  • stroke
  • Alzheimer’s
  • Parkinson’s disease
  • Huntington’s
  • cerebral palsy
  • opiate addiction
  • PTSD
  • Complex regional pain syndrome (CRPS)
  • traumatic brain injury (TBI)
  • epilepsy

In addition to observations in the clinical setting, this team has also published pre-clinical research defining this primary mechanism as a therapeutic target in these additional pathologies:

  • diabetic neuropathy
  • concussion
  • chronic pain
  • depression

These discoveries in neuroimmunology amount to a paradigm shift in understanding of brain dysfunction. The public will only benefit from these discoveries when they are translated into effective treatments and prevention methods for the above dysfunctions. This is what we are committed to achieve at the Brain-Body Research Institute.